Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Cash & Equivalents: 2023-2025

Historic Cash & Equivalents for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $272.6 million.

  • Immunome's Cash & Equivalents rose 75.25% to $272.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $272.6 million, marking a year-over-year increase of 75.25%. This contributed to the annual value of $143.4 million for FY2024, which is 45.27% up from last year.
  • Per Immunome's latest filing, its Cash & Equivalents stood at $272.6 million for Q3 2025, which was up 89.46% from $143.9 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Cash & Equivalents registered a high of $272.6 million during Q3 2025, and its lowest value of $38.4 million during Q2 2023.
  • In the last 3 years, Immunome's Cash & Equivalents had a median value of $143.9 million in 2025 and averaged $152.8 million.
  • Per our database at Business Quant, Immunome's Cash & Equivalents spiked by 507.16% in 2024 and then fell by 12.96% in 2025.
  • Immunome's Cash & Equivalents (Quarterly) stood at $98.7 million in 2023, then surged by 45.27% to $143.4 million in 2024, then surged by 75.25% to $272.6 million in 2025.
  • Its Cash & Equivalents stands at $272.6 million for Q3 2025, versus $143.9 million for Q2 2025 and $257.6 million for Q1 2025.